Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer

(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and pertuzumab (Perjeta) maintenance…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcsvideopearls/119134

Author :

Publish date : 2025-12-22 17:56:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer

Next-Gen Oral SERD Cuts Recurrence Risk in Early Breast Cancer

Is Art the Missing Tool From Modern Healthcare?

Related Posts

How Often Do Physicians Encounter ‘Difficult’ Patients?

Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer

Multiple Sclerosis Risk May Start Before Birth

CAR-Like T Cells Enhance Tumor Response in Gastroesophageal Cancer

Less Favored Airway Device in Cardiac Arrest Had Higher Success Rate

Pompeii’s public baths were unhygienic until the Romans took over

How Often Do Physicians Encounter ‘Difficult’ Patients?

Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer

Multiple Sclerosis Risk May Start Before Birth

CAR-Like T Cells Enhance Tumor Response in Gastroesophageal Cancer

Less Favored Airway Device in Cardiac Arrest Had Higher Success Rate

Pompeii’s public baths were unhygienic until the Romans took over

Court Orders HHS to Restore $12 Million in Funding for AAP Grants

HPV Vaccine Uptake Is Too Low for Herd Immunity

Categories

Archives